CureMatch
×
  • Physicians
    • Patients
  • About Us
  • News
    • CureMatch News
    • Validation and Research
    • Events & Conferences
  • Contact

SOTERIA and CureMatch Partner to Support Oncologists with Personalized Cancer Treatment Options

SOTERIA and CureMatch Partner to Support Oncologists with Personalized Cancer Treatment Options
Partners

SAN DIEGO, CA – April 25 , 2018: SOTERIA Precision Medicine Advisory, Inc. and CureMatch, Inc. have entered into an agreement that will facilitate the delivery of Personalized Combination Therapy® options to the global cancer care community. SOTERIA, the premier concierge precision medicine advisory company, provides client guidance related to individualized tumor profiling services. In turn, CureMatch evaluates a patient’s sequencing data and prior drug history to rank the top mono-therapies, two-drug combinations, and three-drug combinations along with any specifically selected treatment options for the oncologists’ consideration.

“Next-generation tumor sequencing offers insights into the unique biological basis of each individual’s cancer,” stated Aaron Miller, M.D., Ph.D. from UC San Diego Moores
Cancer Center. “Soteria and CureMatch are optimizing the implications of these tests, creating tangible value for oncologists and their patients.”

“SOTERIA is proud to work with CureMatch, the leader in predictive analytics for targeted combination cancer treatment,” stated Julia Civardi, Chief Executive Officer of SOTERIA. “This partnership empowers oncologists with specific treatment recommendations from a molecular basis, so patients receive truly personalized precision medicine.”

“CureMatch is delighted that SOTERIA will help more cancer patients access Personalized Combination Therapy,” stated Stephane Richard, Ph.D, President and Chief Executive Officer of CureMatch.

“Selecting the most promising combinations of anticancer drugs for each individual can be a daunting task, but CureMatch streamlines over 4.5 million drug combinations into actionable analysis for oncologists.”

Chief Science Officer of SOTERIA, Dr. Ashley Brenton, adds, “We have already had tremendous success using CureMatch’s custom analytics to offer personalized, targeted combination therapies for a number of our clients. In many cases, these are patients for whom frontline cancer therapy failed. We look forward to this partnership facilitating therapeutic decision-making in oncology.”

The strategic SOTERIA-CureMatch partnership exemplifies a new way of thinking about cancer care. Instead of traditional tumor site-based treatment, genomics-based precision medicine allows oncologists to target the specific molecular aberrations involved in a patient’s unique cancer.

###

About CureMatch®
CureMatch, Inc. is a digital precision oncology company bridging the gap between legacy cancer treatments and advances in personalized medicine. CureMatch scores and ranks Personalized Combination Therapy® options to target specific molecular aberrations in cost-effective PreciGENE reports. This actionable intelligence guides oncologists to effectively customize treatment for each individual patient. Based in San Diego, CA, the CureMatch technology has expert foundation in supercomputing, oncology, genetics, proteomics, biochemistry, and cell biology. For more information, visit www.curematch.com

About SOTERIA Precision Medicine Advisory
SOTERIA provides patients and physicians with the answers and information they need to navigate the rapidly changing landscape of precision medicine. SOTERIA works on behalf of its international clientele to: identify optimal, personalized genetic testing and genomic sequencing options, provide context and meaning to DNA reports and data, optimize the collection and use of biological specimens and raw sequence data, and to facilitate communication between hospitals, research institutions, and biotechnology companies, on a global basis. Privately-held SOTERIA is headquartered in San Diego, CA. For additional information, visit soteriaone.com

CureMatch Media Contact:
Name: Larissa Anderson
Company: CureMatch
Phone: (858) 859-2873
Email: press@curematch.com

SOTERIA Media Contact:
Name: Jayna Athas
Company: SOTERIA
Phone (858) 539-6004
Email: jayna@SOTERIAone.com

View the official press release here.

 

Share

  • LinkedIn
  • Facebook
  • Twitter
  • Reddit
  • Email
  • Print

Receive CureMatch News

Sign up for personalized oncology information and resources.
* = required field

Recent News & Resources

  • CureMatch Appoints Visionary Leader, Ally Perlina, as Chief Science Officer

    Leader brings two decades of industry experience in precision medicine, pharmaceutical and translational science to...

  • Biomarkers Aren’t Consistently Used to Select Participants for Immunotherapy Trials

    Only a minority of clinical trials evaluating immunotherapeutic agents in 2019 used a biomarker to...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for patients with cancer....

  • Servier and CureMatch® Launch Their Self-Certified CE-Marked Clinical Decision Support Software, Bionov™

    PARIS and SAN DIEGO, Oct. 12, 2020 /PRNewswire/ — WeHealth™ Digital Medicine, Servier Group’s e-health business unit, and CureMatch®, a...

  • How Precision Medicine Can Help You

    Precision medicine is revolutionizing cancer care. Dr. Razelle Kurzrock highlights how personalized treatments improve patient...

  • 64 FDA-Approved Drugs Identified as Potential Treatments for COVID-19

    Scientists from CureMatch and UCSD use pharmacophore-based drug design and a molecular docking technique to...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription drugs in the...

Validation

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription...

  • CureMatch at WIN Symposium 2018 Winning the War against Cancer with Precision Oncology

    SAN DIEGO, CA – June 22, 2018 – CureMatch, Inc. offers results...

  • Personalized Drug Combinations Can Lead to Better Results for Cancer Patients

    A featured article in The Scientist magazine highlights CureMatch co-founder Dr. Razelle...

Archives

  • December 2020 (2)
  • October 2020 (3)
  • April 2020 (1)
  • November 2019 (2)
  • September 2019 (1)
  • August 2019 (1)
  • July 2019 (2)
  • March 2019 (2)
  • September 2018 (1)
  • August 2018 (1)
  • July 2018 (1)
  • June 2018 (5)
  • May 2018 (1)
  • April 2018 (4)
  • March 2018 (1)
  • February 2018 (3)
  • January 2018 (4)
  • December 2017 (3)
  • November 2017 (1)
  • October 2017 (1)
  • September 2017 (3)
  • August 2017 (4)
  • June 2017 (6)
  • May 2017 (9)
  • April 2017 (11)
  • March 2017 (8)
  • February 2017 (3)
  • January 2017 (5)
  • October 2016 (1)
  • September 2016 (5)
  • August 2016 (2)
  • May 2016 (1)
  • April 2016 (1)

logo

+1 (858) 859-2873

FAX: +1 (858) 430-5813

Quick Links

  • Physicians
  • About CureMatch
  • News and Latest Posts
    • CureMatch News
    • Validation and Case Studies
    • Events and Conferences
  • Contact Us
  • FAQ

Latest News and Results

  • CureMatch Appoints Visionary Leader, Ally Perlina, as Chief Science Officer Dec 15

    Leader brings two decades of industry experience in precision medicine, pharmaceutical and translational science to...

  • Biomarkers Aren’t Consistently Used to Select Participants for Immunotherapy Trials Dec 13

    Only a minority of clinical trials evaluating immunotherapeutic agents in 2019 used a biomarker to...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy Oct 19

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for patients with cancer....

© 2021 CureMatch, Inc. CureMatch is a registered trademark.
FAQ | Terms of Use | Privacy Policy | HIPAA Notice

We’d like to send you a CureMatch Sample Analysis

 

Sample Analysis Download Form

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data